Data / Form D filings / Oral Genome Corp.
Oral Genome Corp.: Form D filings
Oral Genome Corp., a biotechnology company in Carlsbad, CA, filed 4 Form D notices with the SEC between 2021 and 2025. The latest, on January 31, 2025, reports $3.1 million sold of a $5.1 million offering to 37 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 7720 RANCHO SANTA FE RD., SUITE 225, Carlsbad, CA, 92009
- Phone
- (360) 349-0790
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2021
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1892288
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 31, 2025 | New notice | $5,107,595 | $3,107,595 | $2,000,000 | 37 | Jan 14, 2025 | sec.gov |
| Nov 23, 2022 | New notice | $75,000 | $75,000 | 1 | Nov 9, 2022 | sec.gov | |
| Apr 25, 2022 | New notice | $13,050 | $13,050 | 1 | Apr 20, 2022 | sec.gov | |
| Nov 5, 2021 | New notice | $30,000 | $30,000 | 1 | Oct 21, 2021 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Tim Pranger | Director | |
| Tina Saw | Executive Officer, Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Jan 27, 2025 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Oral Genome Corp. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.